Hypertrophic obstructive cardiomyopathy: Surgical myectomy and septal ablation

Circulation Research

Volumn 121, Issue 7, 2017, Pages 771-783

  Nishimura, Rick A ^a   Seggewiss, Hubert ^b   Schaff, Hartzell V ^c  

^a MAYO CLINIC   (United States)

^b Leopoldina Krankenhaus   (Germany)

^c Department of Cardiovascular Surgery ^*  (United States)

Author keywords

Athletes; Blood pressure; Cardiomyopathy; Dyspnea; Hypertrophic; Hypertrophy

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ABLATION THERAPY; ARTICLE; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HEART BLOOD VESSEL; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART SEPTUM; HEART SURGERY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MITRAL VALVE; MUSCLE RESECTION; PATIENT SELECTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SEPTAL ABLATION; SEPTAL PERFORATOR ARTERY; SUDDEN DEATH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; TREATMENT RESPONSE; ADVERSE EFFECTS; CARDIAC IMAGING; CARDIAC MUSCLE; CARDIOMYOPATHY, HYPERTROPHIC; CONVALESCENCE; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION; GENETICS; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ABLATION TECHNIQUES; CARDIAC IMAGING TECHNIQUES; CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HEART SEPTUM; HEMODYNAMICS; HUMANS; MYOCARDIUM; PATIENT SELECTION; PHENOTYPE; RECOVERY OF FUNCTION; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 85030613629     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309348     Document Type: Article

References (109)

1. Authors/Task Force Members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014. 35:2733–2779.
2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:783–831.
3. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242–255. doi: 10.1016/S0140-6736(12)60397-3.
4. Nishimura RA, Holmes DR Jr. Clinica`l practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350:1320–1327. doi: 10.1056/NEJMcp030779.
5. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–770. doi: 10.1161/CIRCRESAHA.117.311059.
6. Maron BJ. Sudden death in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:368–380. doi: 10.1007/s12265-009-9147-0.
7. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy: a common cause of sudden death in the young competitive athlete. Eur Heart J. 1983;4(suppl F):135–144.
8. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;28:650–655.
9. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30:3–119.
10. Wigle ED, David PR, Labroose CJ, Mcmeekan J. Muscular subaortic stenosis; the interrelation of wall tension, outflow tract “distending pressure” and orifice radius. Am J Cardiol. 1965;15:761–772.
11. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–2239. doi: 10.1161/CIRCULATIONAHA.106.644682.
12. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored … until now. Am J Med. 2017;130:119–123. doi: 10.1016/j.amjmed.2016.09.015.
13. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy: the search for obstruction. Circulation. 2006;114:2200–2202. doi: 10.1161/CIRCULATIONAHA.106.660928.
14. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303–309. doi: 10.1016/j.jtcvs.2011.10.059.
15. Brock R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp Rep. 1957;106:221–238.
16. Shah PM, Gramiak R, Kramer DH. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation. 1969;40:3–11.
17. Sherrid MV. Pathophysiology and treatment of hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2006;49:123–151. doi: 10.1016/j.pcad.2006.08.001.
18. Nishimura RA, Tajik AJ, Reeder GS, Seward JB. Evaluation of hypertrophic cardiomyopathy by Doppler color flow imaging: initial observations. Mayo Clin Proc. 1986;61:631–639.
19. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28:1–83.
20. Wigle ED. Hypertrophic cardiomyopathy: a 1987 viewpoint. Circulation. 1987;75:311–322.
21. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418–428.
22. Ong KC, Geske JB, Klarich KW, Nishimura RA. A notch in time: midventricular hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2014;15:1288. doi: 10.1093/ehjci/jeu124.
23. Goel K, Schaff HV, Nishimura RA. Natural history of apical hypertrophic cardiomyopathy and novel surgical treatment. J Thorac Cardiovasc Surg. 2016;152:626–627. doi: 10.1016/j.jtcvs.2016.03.017.
24. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010–2020. doi: 10.1093/eurheartj/eht439.
25. Braunwald E, Ebert PA. Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Am J Cardiol. 1962;10:489–495.
26. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AJ. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435–441.
27. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181–189.
28. Kirklin JW, Ellis FH Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation. 1961;24:739–742.
29. Brock R. Aortic subvalvar stenosis: surgical treatment. Guys Hosp Rep. 1959;108:144–158.
30. Morrow AG. Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J Thorac Cardiovasc Surg. 1978;76:423–430.
31. Messmer BJ. Extended myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 1994;58:575–577.
32. Schaff HV, Said SM. Transaortic extended septal myectomy for hypertrophic cardiomyopathy. Oper Tech Thorac Cardiovasc Surg. 2012;17:238–250.
33. Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z, Ommen SR. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68:1497–1504. doi: 10.1016/j.jacc.2016.07.735.
34. Rowin EJ, Maron BJ, Lesser JR, Rastegar H, Maron MS. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. Am J Cardiol. 2013;111:1677–1679. doi: 10.1016/j.amjcard.2013.01.340.
35. Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to guide surgical myectomy for hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:53–59. doi: 10.1016/j.jtcvs.2010.08.011.
36. Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66:1307–1308. doi: 10.1016/j.jacc.2015.06.1333.
37. Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, Naidu SS, Gade CL, Charitakis K, Singh HS, Feldman DN. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol. 2016;1:324–332.
38. Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130:1617–1624. doi: 10.1161/CIRCULATIONAHA.114.011580.
39. Mohr R, Schaff HV, Puga FJ, Danielson GK. Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age. Circulation. 1989;80:I191–I196.
40. Cho YH, Quintana E, Schaff HV, Nishimura RA, Dearani JA, Abel MD, Ommen S. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148:909–915; discussion 915–916.
41. Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, Williams WG, Schwartz L, Guttman A, Woo A. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313–2321. doi: 10.1016/j.jacc.2011.08.040.
42. Desai MY, Smedira NG, Bhonsale A, Thamilarasan M, Lytle BW, Lever HM. Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes. J Thorac Cardiovasc Surg. 2015;150:928–935.e1. doi: 10.1016/j.jtcvs.2015.07.063.
43. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–476. doi: 10.1016/j.jacc.2005.02.090.
44. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583–2588. doi: 10.1093/eurheartj/ehm117.
45. Nishimura RA, Schaff HV. Septal myectomy for patients with hypertrophic cardiomyopathy: a new paradigm. J Thorac Cardiovasc Surg. 2016;151:303–304. doi: 10.1016/j.jtcvs.2015.09.068.
46. Ommen SR, Park SH, Click RL, Freeman WK, Schaff HV, Tajik AJ. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am J Cardiol. 2002;90:1022–1024.
47. Hong JH, Schaff HV, Nishimura RA. Fixed versus dynamic subaortic stenosis: hemodynamics and resulting differences in Doppler echocardiography and aortic pressure contour. J Thorac Cardiovasc Surg. 2016;151:883–884. doi: 10.1016/j.jtcvs.2015.10.082.
48. Hong J, Schaff HV, Ommen SR, Abel MD, Dearani JA, Nishimura RA. Mitral stenosis and hypertrophic obstructive cardiomyopathy: an unusual combination. J Thorac Cardiovasc Surg. 2016;151:1044–1048. doi: 10.1016/j.jtcvs.2015.11.048.
49. Klarich KW, Attenhofer Jost CH, Binder J, Connolly HM, Scott CG, Freeman WK, Ackerman MJ, Nishimura RA, Tajik AJ, Ommen SR. Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol. 2013;111:1784–1791. doi: 10.1016/j.amjcard.2013.02.040.
50. Schaff HV, Brown ML, Dearani JA, Abel MD, Ommen SR, Sorajja P, Tajik AJ, Nishimura RA. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2010;139:634–640. doi: 10.1016/j.jtcvs.2009.07.079.
51. Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, Ommen SR. Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg. 2013;96:564–570. doi: 10.1016/j.athoracsur.2013.04.073.
52. Maron BJ. Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. Am J Cardiol. 2015;116:332–334. doi: 10.1016/j.amjcard.2015.04.027.
53. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–214.
54. Sigwart U. Discount treatment for HOCM: as good as surgery? Eur Heart J. 2016;37:1524–1525. doi: 10.1093/eurheartj/ehw038.
55. Sigwart U, Grbic M, Essinger A, Bischof-Delaloye A, Sadeghi H, Rivier JL. Improvement of left ventricular function after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1982;49:651–657.
56. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J. 1997;18:846–851.
57. Come PC, Riley MF. Hypertrophic cardiomyopathy. Disappearance of auscultatory, carotid pulse, and echocardiographic manifestations of obstruction following myocardial infarction. Chest. 1982;82:451–454.
58. Brugada P, de Swart H, Smeets JL, Wellens HJ. Transcoronary chemical ablation of ventricular tachycardia. Circulation. 1989;79:475–482.
59. Goodwin JF, Oakley CM. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:1624.
60. Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients withobstructivehypertrophiccardiomyopathy.Circulation.2007;116:196–206; discussion 206. doi: 10.1161/CIRCULATIONAHA.107.691378.
61. Braunwald E. A new treatment for hypertrophic cardiomyopathy? Eur Heart J. 1997;18:709–710.
62. Braunwald E. Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. Circulation. 1997;95:1981–1982.
63. Seggewiss H. Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Neth Heart J. 2001;9:315–317.
64. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415–2421.
65. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep. 2001;3:160–166.
66. Pfeiffer B, Rigopoulos A, Seggewiß H. [Myocardial contrast echocardiography guided alcohol septal ablation in hypertrophic obstructive cardiomyopathy with a new echocardiographic contrast agent]. Dtsch Med Wochenschr. 2012;137:2093–2096. doi: 10.1055/s-0032-1305229.
67. Rigopoulos A, Sepp R, Palinkas A, Ungi I, Kremastinos DT, Seggewiss H. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: collateral vessel communication between septal branches. Int J Cardiol. 2006;113:e67–e69. doi: 10.1016/j.ijcard.2006.04.057.
68. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr. 2004;5:347–355. doi: 10.1016/j.euje.2004.01.001.
69. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19:319–327. doi: 10.1111/j.1540-8183.2006.00153.x.
70. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D. [Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy]. Z Kardiol. 2003;92:39–47. doi: 10.1007/s00392-003-0878-7.
71. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation. 2002;106:454–459.
72. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342–1354. doi: 10.1053/euhj.1999.1520.
73. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol. 2000;36:852–855.
74. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750–1755.
75. Seggewiss H. Percutaneous alcohol ablation in HOCM. Catheter Cardiovasc Interv. 1999;48:241–242.
76. Seggewiss H, Faber L, Ziemssen P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev. 1999;7:316–323.
77. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2007;96:856–863. doi: 10.1007/s00392-007-0579-8.
78. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131–139. doi: 10.1161/CIRCULATIONAHA.107.738740.
79. van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Götte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111:2503–2508. doi: 10.1161/01.CIR.0000165084.28065.01.
80. Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35:2040–2045. doi: 10.1093/eurheartj/eht495.
81. Veselka J, Procházková S, Duchonová R, Bolomová-Homolová I, Pálenícková J, Tesar D, Cervinka P, Honek T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv. 2004;63:231–235. doi: 10.1002/ccd.20176.
82. Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv. 1999;47:462–466. doi: 10.1002/(SICI)1522-726X(199908)47:4<462::AID-CCD16>3.0.CO;2-9.
83. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119:163–167. doi: 10.1016/j.ijcard.2006.07.179.
84. Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation. 2007;116:207–216; discussion 216. doi: 10.1161/CIRCULATIONAHA.107.688135.
85. Veselka J, Zemánek D, Tomasov P, Homolová S, Adlová R, Tesar D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv. 2010;75:546–550. doi: 10.1002/ccd.22326.
86. Burri H, Sigwart U. Technology insight: transcoronary ablation of septal hypertrophy. Nat Clin Pract Cardiovasc Med. 2005;2:101–107. doi: 10.1038/ncpcardio0095.
87. Jensen MK, Havndrup O, Hassager C, Helqvist S, Kelbæk H, Jørgensen E, Køber L, Bundgaard H. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy. Scand Cardiovasc J. 2011;45:153–160. doi: 10.3109/14017431.2011.565793.
88. Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–2380. doi: 10.1161/CIRCULATIONAHA.111.076257.
89. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517–1523. doi: 10.1093/eurheartj/ehv693.
90. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc. 2001;76:799–802.
91. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, Spencer WH 3rd. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008;1:561–570.
92. Rigopoulos AG, Panou F, Kremastinos DT, Seggewiss H. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Hellenic J Cardiol. 2009;50:511–522.
93. Ruzyłło W, Chojnowska L, Demkow M, Witkowski A, Kuśmierczyk-Droszcz B, Piotrowski W, Rausinska L, Karcz M, Małecka L, Rydlewska-Sadowska W. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J. 2000;21:770–777. doi: 10.1053/euhj.1999.1905.
94. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96:864–873. doi: 10.1007/s00392-007-0578-9.
95. Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, Bundgaard H. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99:1012–1017. doi: 10.1136/heartjnl-2012-303339.
96. Nishimura RA, Ommen SR. Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. Circ Cardiovasc Interv. 2010;3:91–93. doi: 10.1161/CIRCINTERVENTIONS.110.952085.
97. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:350–357. doi: 10.1016/j.jacc.2006.08.055.
98. Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Mela T, Das S. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104:128–132. doi: 10.1016/j.amjcard.2009.02.056.
99. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362–369. doi: 10.1161/CIRCHEARTFAILURE.109.862359.
100. Sawaya FJ, Louvard Y, Spaziano M, et al. Short and long-term outcomes of alcohol septal ablation with the trans-radial versus the trans-femoral approach: a single center-experience. Int J Cardiol. 2016;220:7–13. doi: 10.1016/j.ijcard.2016.06.127.
101. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol. 2008;97:234–243. doi: 10.1007/s00392-007-0616-7.
102. Kwon DH, Kapadia SR, Tuzcu EM, Halley CM, Gorodeski EZ, Curtin RJ, Thamilarasan M, Smedira NG, Lytle BW, Lever HM, Desai MY. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc Interv. 2008;1:432–438. doi: 10.1016/j.jcin.2008.05.009.
103. Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Køber L, Endresen K, Eriksson MJ, Jørgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4:256–265. doi: 10.1161/CIRCINTERVENTIONS.110.959718.
104. Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Bundgaard H, Steggerda R, Faber L. Low procedure-related mortality achieved with alcohol septal ablation in European patients. Int J Cardiol. 2016;209:194–195. doi: 10.1016/j.ijcard.2016.02.077.
105. Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate FJ, van Cleemput J, Ten Berg JM, Michels M. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2:630–636. doi: 10.1016/j.jchf.2014.06.012.
106. Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7:1227–1234. doi: 10.1016/j.jcin.2014.05.023.
107. Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2016;105:953–961. doi: 10.1007/s00392-016-1005-x.
108. Seggewiss H, Blank C, Pfeiffer B, Rigopoulos A. Hypertrophic cardiomyopathy as a cause of sudden death. Herz. 2009;34:305–314. doi: 10.1007/s00059-009-3248-z.
109. Rigopoulos AG, Seggewiss H. Twenty years of alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Curr Cardiol Rev. 2015;12:286–296.